Aprilbio Co., Ltd.
KKRX:39703012,750.00
KRW
-350.00
(-2.67%)
ISIN
KR7397030008
Return %
Stock
S&P 500
1Y
-55.73
14.39
3Y
18.88
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sang-Hun Cha
- Full Time Employees
- 27
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Chuncheon-si South Korea
- IPO Date
- Jul 28, 2022
- Website
- aprilbio.com
- Similar Companies
- Business
- Aprilbio Co., Ltd. is a clinical-stage biopharmaceutical company that engages in the research, development, and commercialization of novel biologics, long-acting antibody therapeutics, and platform-driven drug discovery solutions for autoimmune disorders, inflammatory conditions, and oncology indications. Founded in 2013 and headquartered in Chuncheon, South Korea, with corporate and research operations in Seoul, the company focuses on creating therapeutic candidates with extended half-lives and enhanced safety profiles through proprietary engineering technologies. Aprilbio offers a pipeline of preclinical and clinical-stage therapeutics and proprietary platform solutions, including APB-R3 (EVO301), a long-acting recombinant interleukin-18 (IL-18) binding protein fusion candidate designed for the treatment of inflammatory diseases such as atopic dermatitis; APB-A1 (Lu AG22515), a humanized antagonistic CD40 ligand (CD40L) blocking antibody therapeutic engineered for neuroimmunological and autoimmune conditions, including multiple sclerosis, neuromyelitis optica spectrum disorder, and thyroid eye disease; APB-R5, an oncology-targeted biologic candidate; APB-BS2, a pipeline of bispecific and multi-targeted antibody therapeutics; the SAFA (anti-Serum Albumin Fab-Associated) platform, a proprietary half-life extension technology that utilizes anti-human serum albumin antibody fragments to prolong in vivo drug retention; and the REMAP platform, an advanced multi-modality engineering technology designed to integrate antibodies, peptides, antibody-drug conjugates, and nucleic acid therapeutics. The company serves global pharmaceutical and biotechnology corporations across North America, Europe, and the Asia-Pacific region through technology transfer, out-licensing, and collaborative development arrangements. In recent developments, Aprilbio executed an exclusive global licensing agreement with U.S.-based Evommune, Inc. for the clinical advancement and commercialization of APB-R3, while progressing its clinical partnership with Denmark-based H. Lundbeck A/S for APB-A1 across expanded neuroimmunological indications. The company also secured substantial strategic investment and entered into a management partnership led by a consortium comprising TKG Huchems and IMM Investment Group to accelerate internal clinical development, and broadened its therapeutic scope into RNA modalities via a license-in agreement with Qurient Co., Ltd. for dual-target siRNA-based metabolic disease candidates.